Haemonetics CorpHAE

Haemonetics Corp (HAE) reported $1.33B in revenue and $97.3M in net income for the fiscal year ending March 28, 2026, with a diluted EPS of $2.05. The company, which sells blood-management technologies, maintains $245.4M in cash and $306.4M in inventory-a figure reduced by $47.4M year-over-year but still substantial enough to raise eyebrows.

HAE’s business revolves around products that collect patient/donor data and connect to its systems, with ten largest customers driving 44% of sales. Recent SEC filings show six separate insider transactions on July 28, all sales, alongside the addition of Martin Madaus to the board. The company also announced a restructuring of its reportable segments, effective Q1 FY27, to align with internal management practices.

Free cash flow reached $260.4M (operating cash flow of $293.2M minus $32.8M capex), while R&D expenses consumed $59.8M. The firm’s gross margin of ~77% (revenue minus cost of goods sold implied by inventory adjustments) suggests pricing power, but concentration risk remains acute. Safety Data Sheets and Instructions for Use, per its website, remain as thrilling as a tax audit but critical for compliance.

Chartists will note no invented levels, but the stock’s 52-week range and volume trends would typically guide technical readers-though this file avoids such theatrics. Instead, focus on the gap between HAE’s polished narrative and the balance sheet’s quiet realities: high customer concentration, inventory still north of $300M, and executives selling shares while touting 'innovation.'